MDMA-assisted therapy facilitates profound psychological breakthroughs by reducing fear and defensiveness while increasing empathy and introspection. From a healthspan perspective, its primary value lies in resolving severe psychological trauma (e.g., PTSD), which is a significant driver of chronic stress, inflammation, and accelerated biological aging. By addressing the root psychological drivers of allostatic load, it may indirectly improve long-term physiological resilience and reduce the burden of stress-related disease.
Verdict
A powerful, high-risk tool for resolving trauma-driven accelerated aging.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$10000 - $15000
Protocol
- A full therapeutic course typically involves 2-3 sessions, each with a single 80-120mg dose.
- Administered under strict medical supervision with integrated psychotherapy before, during, and after dosing.
Flags
- Currently a Schedule I controlled substance in the US, only legally available in clinical trials or via expanded access.
- Significant risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs.
- Poses acute cardiovascular risks (hypertension, tachycardia); contraindicated for individuals with heart conditions.
- Potential for neurotoxicity with frequent or high-dose recreational use, distinct from clinical protocols.
- Must be conducted in a controlled, therapeutic setting with trained professionals.